急性冠脉综合征中肠道微生物依赖性氧化三甲胺:超越传统危险因素的突发心血管事件预后标志物
在克利夫兰队列(n=530)和瑞士多中心队列(n=1683)的急性冠脉综合征患者中,血浆氧化三甲胺(TMAO)水平升高与主要不良心脏事件(MACE)风险独立相关。在克利夫兰队列中,TMAO最高四分位组30天MACE的校正OR为6.30(95%CI 1.89-21.0,P<0.01),6个月MACE的校正OR为5.65(95%CI 1.91-16.7,P<0.01),7年死亡率的校正HR为1.81(95%CI 1.04-3.15,P<0.05)。在瑞士队列中,TMAO最高四分位组1年MACE的校正HR为1.57(95%CI 1.03-2.41,P<0.05)。
要点
- 在克利夫兰队列中,就诊时血浆TMAO最高四分位组30天MACE的校正OR为6.30(95%CI 1.89-21.0,P<0.01)。
- 在克利夫兰队列中,TMAO最高四分位组6个月MACE的校正OR为5.65(95%CI 1.91-16.7,P<0.01),7年死亡率的校正HR为1.81(95%CI 1.04-3.15,P<0.05)。
- 在瑞士队列中,TMAO最高四分位组1年MACE的校正HR为1.57(95%CI 1.03-2.41,P<0.05)。
核心结论
- 在因胸痛就诊的患者中,血浆TMAO水平可预测近期和远期突发心血管事件风险,可能有助于疑似急性冠脉综合征患者的风险分层。
研究设计与样本
- 研究包含两个独立队列:克利夫兰队列为连续因疑似心源性胸痛至急诊科就诊的患者(n=530);瑞士多中心队列为接受冠状动脉造影的急性冠脉综合征患者(n=1683)。
主要发现
- 在克利夫兰队列中,就诊时血浆TMAO水平升高与30天MACE风险独立相关(最高四分位组校正OR 6.30,95%CI 1.89-21.0,P<0.01)。
- 在克利夫兰队列中,TMAO水平升高与6个月MACE风险独立相关(最高四分位组校正OR 5.65,95%CI 1.91-16.7,P<0.01)。
- 在克利夫兰队列中,TMAO水平是长期(7年)死亡率的显著预测因子(最高四分位组校正HR 1.81,95%CI 1.04-3.15,P<0.05)。
- 在克利夫兰队列中,初始肌钙蛋白T阴性(<0.1 ng/mL)的受试者中,就诊时TMAO水平仍可预测30天MACE风险(最高四分位组校正OR 5.83,95%CI 1.79-19.03,P<0.01)。
- 在瑞士队列中,TMAO可预测1年MACE风险增加(最高四分位组校正HR 1.57,95%CI 1.03-2.41,P<0.05)。
临床怎么用
- 原文结论指出,血浆TMAO水平可能为疑似急性冠脉综合征患者的风险分层提供临床效用。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: Systemic levels of trimethylamine N-oxide (TMAO), a pro-atherogenic and pro-thrombotic metabolite produced from gut microbiota metabolism of dietary trimethylamine (TMA)-containing nutrients such as choline or carnitine, predict incident cardiovascular event risks in stable primary and secondary prevention subjects. However, the prognostic value of TMAO in the setting of acute coronary syndromes (ACS) remains unknown. METHODS AND RESULTS: We investigated the relationship of TMAO levels with incident cardiovascular risks among sequential patients presenting with ACS in two independent cohorts. In the Cleveland Cohort, comprised of sequential subjects (n = 530) presenting to the Emergency Department (ED) with chest pain of suspected cardiac origin, an elevated plasma TMAO level at presentation was independently associated with risk of major adverse cardiac events (MACE, including myocardial infarction, stroke, need for revascularization, or death) over the ensuing 30-day (4th quartile (Q4) adjusted odds ratio (OR) 6.30, 95% confidence interval (CI), 1.89-21.0, P < 0.01) and 6-month (Q4 adjusted OR 5.65, 95%CI, 1.91-16.7; P < 0.01) intervals. TMAO levels were also a significant predictor of the long term (7-year) mortality (Q4 adjusted HR 1.81, 95%CI, 1.04-3.15; P < 0.05). Interestingly, TMAO level at initial presentation predicted risk of incident MACE over the near-term (30 days and 6 months) even among subjects who were initially negative for troponin T (< 0.1 ng/mL) (30 days, Q4 adjusted OR 5.83, 95%CI, 1.79-19.03; P < 0.01). The prognostic value of TMAO was also assessed in an independent multicentre Swiss Cohort of ACS patients (n = 1683) who underwent coronary angiography. Trimethylamine N-oxide again predicted enhanced MACE risk (1-year) (adjusted Q4 hazard ratios: 1.57, 95% CI, 1.03-2.41; P <0.05). CONCLUSION: Plasma TMAO levels among patients presenting with chest pain predict both near- and long-term risks of incident cardiovascular events, and may thus provide clinical utility in risk stratification among subjects presenting with suspected ACS.
引用
- Li XS, Obeid S, Klingenberg R, et al. Gut microbiota-dependent trimethylamine N-oxide in acute coronary syndromes: a prognostic marker for incident cardiovascular events beyond traditional risk factors. Eur Heart J. 2017. PMID: 28077467. doi:10.1093/eurheartj/ehw582
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。